Compound class:
Synthetic organic
Comment: We obtained the chemical structure for culmerciclib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a cyclin-dependent kinase inhibitor and antineoplastic. This Chemical structure mapped to PubChem CID 122544510, and to a structure in Nanjing Mingde New Drug Research and Development Company's patent WO2016141881A1 [1] which claims selective CDK4/6 inhibitors as anticancer drugs.
|
|
Bioactivity Comments |
We have been unable to find quantitative data for culmerciclib at its proposed molecular target(s). |